NBL1 Gene: A New Driver of Ovarian Cancer Metastasis, Offering a Therapeutic Target via Jak/Stat3 Pathway
- Sep 23
- 2 min read
Ovarian cancer remains one of the most challenging gynecological malignancies, primarily due to its low rates of early detection and poor prognosis. A significant factor contributing to these grim outcomes is transcoelomic metastasis—the spread of cancer cells within the abdominal cavity—which occurs early in the disease and is strongly linked to poor survival. For years, the precise mechanisms driving this spread have been a puzzle for scientists.
Now, a pivotal study from researchers at Tianjin Medical University, Tianjin Central Hospital of Gynecology Obstetrics, and Nankai University sheds new light on this deadly process. Published in the journal Genes & Diseases, the research utilized advanced CRISPR-based genetic screening to identify a gene called neuroblastoma suppressor of tumorigenicity 1 (NBL1) as a critical promoter of ovarian cancer metastasis.
The findings show that NBL1 is significantly overexpressed in metastatic ovarian tumors. This high level of expression is strongly correlated with a more advanced clinical stage and worse survival outcomes for patients. While some previous research had pointed to NBL1 as a potential tumor suppressor gene, this new study reveals a previously unrecognized and dangerous oncogenic role in ovarian cancer.
The team uncovered a dual mechanism through which NBL1 fuels cancer's spread. First, it directly activates the Jak/Stat3 signaling pathway, which is known to be involved in cell proliferation and migration. Second, it actively suppresses the body's own defenses by limiting the infiltration of T cells, which are essential for anti-tumor immunity. This two-pronged attack allows cancer cells to multiply, invade new tissues, and resist apoptosis (programmed cell death).
Perhaps most importantly, the study offers a new avenue for treatment. Researchers demonstrated that a Stat3 inhibitor, Wp1066, could effectively block NBL1-driven metastasis in both laboratory and mouse models. This inhibitor successfully reversed the gene's effects on cell proliferation and migration.
This breakthrough positions NBL1 as both a powerful prognostic biomarker for identifying high-risk patients and, more critically, a promising new therapeutic target. By targeting the NBL1-Jak/Stat3 pathway, it may be possible to develop new treatments to halt the metastatic spread of ovarian cancer and improve patient outcomes.
🔖 Sources
Comments